BioCryst Pharmaceuticals,Inc. (BCRX)

[apollo1452]

What if there is No Dilution??? Stonehouse directly addressed the BCRX cash position for the 3rd+ CC in a row on today's Evercore ISI call:

https://wsw.com/webcast/evercore11/bcrx/2358195

Stonehouse emphasized the strong BCRX cash position into 2021.
$149,000,000 cash on hand, the coming $20,000,000 milestone payment from Torii Pharma, the existing $46,000,000 credit line & the Berotralstat/Orlaydeo sales force is ready to start generating sales pronto upon Dec 3 approval.

Stonehouse once again pointed out the multiple alternatives instead of issuing more shares & he discussed other funding options available to the company including bonds, debt, royalty financing and partnerships.

Shorts are screwed, they have been expecting a BCRX dilution event Q4 2020 to cover their short positions, approximately 20% of the outstanding shares. It ain't happening!

The best clue is CFO Doyle spending half his annual salary to buy BCRX shares on the open market. No CFO would do that if he felt share dilution is likely.

https://seekingalpha.com/news/3604911-biocryst-pharmaplus-5-cfo-buys-220000-worth

The shorts who are not hedged with a BCRX long position are now shorting more to keep a lid on the share price & praying that Orladeyo sales are soft. They are very vulnerable to good Orladeyo sales news but also surprise Galidesivir news, BCX9250 Fibrodysplasia Ossificans Progressiva (FOP) P1 data & the next BCX9930 Factor D inhibitor update.